Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
Clinical trial NCT01171898 · COMPLETED
Trial details
- NCT number
- NCT01171898
- Sponsor
- Aragon Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2010-07-26
- Primary completion
- 2012-08-20
- Enrollment
- 127
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.